Lophius seals a new round of finance
Lophius Biosciences GmbH, founded from the University of Regensburg, develops and markets molecular diagnostic solutions for the transformation of treatment paradigms and patient management in the field of life threatening and highly contagious infectious diseases. As now announced by the biotech company, a finance round of 3.1 million EUR was able to be sealed under the management of VRD GmbH, supported by Wachstumsfonds Bayern (Bavarian Growth Fund) at Bayern Kapital GmbH and private investors. The company will use the funding to expand clinical performance data, complete design optimization and establish the blood-based test to detect tuberculosis infection (TB) on widely automated platforms to facilitate rapid market penetration. In the second half of the year 2020 broad-based clinical validation studies are to be introduced for market licensing.
Lophius has recently reached an important clinical milestone in the development of the company’s own blood-based multi-marker tests for the detection of infection of TB for active and latent TB patients compared with non-infected control individuals: thereby the Lophius solution has exceeded its planned target goals.
In particular more than 95% of the patients with active TB were classified correctly as infected and thereby exceeded the IGRAs (Interferon Gamma Release Assay) as benchmark.
“We are pleased that with these additional funds from our program that a new standard for the diagnosis of TB has been able to be further established. The high level of achievement reached by our blood-based solution makes the early recognition of tuberculosis in diagnostic work-up possible with the potential to significantly improve patient management and reduce health costs. Furthermore with our expertise and our strong network we provide a solid basis to drive forward our highly innovative program: a solution to distinguish between latent tuberculosis and active tuberculosis requiring treatment”, commented Bernd Merkl, CEO of Lophius Biosciences.
Lophius has recently reached an important clinical milestone in the development of the company’s own blood-based multi-marker tests for the detection of infection of TB for active and latent TB patients compared with non-infected control individuals: thereby the Lophius solution has exceeded its planned target goals.
In particular more than 95% of the patients with active TB were classified correctly as infected and thereby exceeded the IGRAs (Interferon Gamma Release Assay) as benchmark.
“We are pleased that with these additional funds from our program that a new standard for the diagnosis of TB has been able to be further established. The high level of achievement reached by our blood-based solution makes the early recognition of tuberculosis in diagnostic work-up possible with the potential to significantly improve patient management and reduce health costs. Furthermore with our expertise and our strong network we provide a solid basis to drive forward our highly innovative program: a solution to distinguish between latent tuberculosis and active tuberculosis requiring treatment”, commented Bernd Merkl, CEO of Lophius Biosciences.
This has allowed a successful company at the BioPark to be supported in its further development with funding from Wachstumsfonds Bayern (Bavarian Growth Fund). Bayern Kapital GmbH with its headquarters in Landshut is a 100 percent subsidiary of the Bavarian LfA Förderbank. Bayern Kapital as a venture capital organization of the State of Bavaria provides equity financing for the startup of young innovative technology companies in Bavaria. Currently Bayern Kapital administrates eleven investment funds with a total volume of around 325 million Euro. To date almost 300 million Euro has been invested in 270 innovative companies in the technology fields including biosciences, software and IT, medical engineering, materials and novel materials, nanotechnology and environmental technology.
For further information see: